80 related articles for article (PubMed ID: 27282150)
1. Study design and data analysis considerations for the discovery of prognostic molecular biomarkers: a case study of progression free survival in advanced serous ovarian cancer.
Qin LX; Levine DA
BMC Med Genomics; 2016 Jun; 9(1):27. PubMed ID: 27282150
[TBL] [Abstract][Full Text] [Related]
2. Plasmin(ogen) serves as a favorable biomarker for prediction of survival in advanced high-grade serous ovarian cancer.
Zhao S; Dorn J; Napieralski R; Walch A; Diersch S; Kotzsch M; Ahmed N; Hooper JD; Kiechle M; Schmitt M; Magdolen V
Biol Chem; 2017 Jun; 398(7):765-773. PubMed ID: 27935848
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.
Andorfer P; Heuwieser A; Heinzel A; Lukas A; Mayer B; Perco P
BMC Syst Biol; 2016 Apr; 10():33. PubMed ID: 27090655
[TBL] [Abstract][Full Text] [Related]
4. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract][Full Text] [Related]
5. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
[TBL] [Abstract][Full Text] [Related]
6. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
[TBL] [Abstract][Full Text] [Related]
7. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
9. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
10. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
[TBL] [Abstract][Full Text] [Related]
11. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
12. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
13. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
14. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
15. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
[TBL] [Abstract][Full Text] [Related]
16. Identification of molecular biomarkers for ovarian cancer using computational approaches.
Lalremmawia H; Tiwary BK
Carcinogenesis; 2019 Jul; 40(6):742-748. PubMed ID: 30753333
[TBL] [Abstract][Full Text] [Related]
17. Prognostic DNA methylation biomarkers in ovarian cancer.
Wei SH; Balch C; Paik HH; Kim YS; Baldwin RL; Liyanarachchi S; Li L; Wang Z; Wan JC; Davuluri RV; Karlan BY; Gifford G; Brown R; Kim S; Huang TH; Nephew KP
Clin Cancer Res; 2006 May; 12(9):2788-94. PubMed ID: 16675572
[TBL] [Abstract][Full Text] [Related]
18. Performance evaluation of transcriptomics data normalization for survival risk prediction.
Ni A; Qin LX
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34245143
[TBL] [Abstract][Full Text] [Related]
19. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract][Full Text] [Related]
20. The CD44 receptor is a molecular predictor of survival in ovarian cancer.
Rodríguez-Rodríguez L; Sancho-Torres I; Mesonero C; Gibbon DG; Shih WJ; Zotalis G
Med Oncol; 2003; 20(3):255-63. PubMed ID: 14514975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
